Klabunde Carrie, Blom Johannes, Bulliard Jean-Luc, Garcia Montse, Hagoel Lea, Mai Verna, Patnick Julietta, Rozjabek Heather, Senore Carlo, Törnberg Sven
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
J Med Screen. 2015 Sep;22(3):119-26. doi: 10.1177/0969141315584694. Epub 2015 May 12.
Participation, an indicator of screening programme acceptance and effectiveness, varies widely in clinical trials and population-based colorectal cancer (CRC) screening programmes. We aimed to assess whether CRC screening participation rates can be compared across organized guaiac fecal occult blood test (G-FOBT)/fecal immunochemical test (FIT)-based programmes, and what factors influence these rates.
Programme representatives from countries participating in the International Cancer Screening Network were surveyed to describe their G-FOBT/FIT-based CRC screening programmes, how screening participation is defined and measured, and to provide participation data for their most recent completed screening round.
Information was obtained from 15 programmes in 12 countries. Programmes varied in size, reach, maturity, target age groups, exclusions, type of test kit, method of providing test kits and use, and frequency of reminders. Coverage by invitation ranged from 30-100%, coverage by the screening programme from 7-67.7%, overall uptake/participation rate from 7-67.7%, and first invitation participation from 7-64.3%. Participation rates generally increased with age and were higher among women than men and for subsequent compared with first invitation participation.
Comparisons among CRC screening programmes should be made cautiously, given differences in organization, target populations, and interpretation of indicators. More meaningful comparisons are possible if rates are calculated across a uniform age range, by gender, and separately for people invited for the first time vs. previously.
参与率作为筛查项目接受度和有效性的一项指标,在临床试验及基于人群的结直肠癌(CRC)筛查项目中差异很大。我们旨在评估基于组织化愈创木脂粪便潜血试验(G-FOBT)/粪便免疫化学试验(FIT)的项目之间CRC筛查参与率是否具有可比性,以及哪些因素会影响这些比率。
对参与国际癌症筛查网络的国家的项目代表进行调查,以描述其基于G-FOBT/FIT的CRC筛查项目、筛查参与度的定义和测量方式,并提供其最近一次完成的筛查轮次的参与数据。
从12个国家的15个项目中获取了信息。各项目在规模、覆盖范围、成熟度、目标年龄组、排除标准、检测试剂盒类型、提供检测试剂盒的方法及使用情况以及提醒频率等方面存在差异。受邀覆盖率从30%至100%不等,筛查项目覆盖率从7%至67.7%不等,总体接受率/参与率从7%至67.7%不等,首次受邀参与率从7%至64.3%不等。参与率一般随年龄增长而升高,女性高于男性,后续受邀参与率高于首次受邀参与率。
鉴于各项目在组织、目标人群及指标解读方面存在差异,对CRC筛查项目进行比较时应谨慎。如果按统一的年龄范围、性别以及首次受邀者与既往受邀者分别计算比率,则可能进行更有意义的比较。